Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry
Authors:
- Richard DeanRDRichard Dean
- Maryam YazdanfarMYMaryam Yazdanfar
- Joseph ZepedaJZJoseph Zepeda
- Cynthia LevyCLCynthia Levy
- Craig LammertCLCraig Lammert
- Daniel PrattDPDaniel Pratt
- Stuart C. GordonSGStuart C. Gordon
- Lisa FormanLFLisa Forman
- David N. AssisDADavid N. Assis
- Ashleigh McGirrAMAshleigh McGirr
- Megan McLaughlinMMMegan McLaughlin
- Sumanta MukherjeeSMSumanta Mukherjee
Open Access
- 16 May 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (6)
Abstract
Background: Cholestasis from primary sclerosing cholangitis (PSC) frequently causes pruritus. However, the prevalence of pruritus and its management have not been well studied. Investigating the Cholestatic Pruritus of Primary Sclerosing Cholangitis (ItCh-PSC) includes a retrospective medical record review to determine the prevalence, severity, and treatment patterns of pruritus. Methods: Data was collected at 5 academic medical centers in the United States. Medical records were searched for the terms “itch” and “pruritus” and data abstracted related to itch severity, number of encounters, and treatment. Results: Among 724 patients with PSC, 359 (50%) of patients had a documented history of pruritus, including 40%, 39%, and 21% with mild, moderate, or severe itch. Itch was less common in those with small ducts compared to large duct PSC (p=0.02) and more frequent in those of Hispanic versus non-Hispanic ethnicity (p=0.001). Compared to patients with mild itch, patients with moderate or severe itch were younger, and had more elevated liver biochemistries, more encounters with itch, and more frequently prescribed 2 or more anti-pruritic medications. Bile acid–binding resins were prescribed in 36%, hydroxyzine in 23%, rifampin in 11%, and fenofibrate in 4% of patients with any itch. The prevalence and severity of pruritus were not affected by cirrhosis, hepatic decompensation, or inflammatory bowel disease. Conclusion: Itch is common in patients with PSC and is often associated with multiple prescriptions of antipruritic agents. Effective treatments for pruritus in patients with PSC remain an unmet need.Keywords
This publication has 29 references indexed in Scilit:
- Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature ReviewDigestive Diseases and Sciences, 2023
- New Treatment Paradigms in Primary Biliary CholangitisClinical Gastroenterology and Hepatology, 2023
- GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With PruritusClinical Gastroenterology and Hepatology, 2022
- AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinomaHepatology, 2022
- Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based StudiesClinical Gastroenterology and Hepatology, 2022
- Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online RegistryClinical Gastroenterology and Hepatology, 2019
- Sertraline as a first-line treatment for cholestatic pruritusHepatology, 2007
- Natural history and prognostic variables in primary sclerosing cholangitisGastroenterology, 1991
- Treatment of pruritus in primary biliary cirrhosis with rifampinGastroenterology, 1988
- Clinicopathologic features of the syndrome of primary sclerosing cholangitisGastroenterology, 1980